2022 American Transplant Congress
Belatacept Augments Mixed Chimerism in a Novel Nonhuman Primate Kidney Transplant Tolerance Induction Protocol
University of Wisconsin, Madison, WI
*Purpose: A novel protocol of antilymphocyte globulin (ATG), tomotherapy-based total lymphoid irradiation (TomoTLI), and adoptive cellular transfer was developed in a preclinical model of MHC-mismatched…2022 American Transplant Congress
Five-Year Follow-Up from a Prospective, Randomized Trial of Belatacept-Based, CNI Free/Early Steroid Withdrawal Regimens
1University of Cincinnati, Cincinnati, OH, 2Christ Hospital, Cincinnati, OH
*Purpose: A prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based, calcineurin inhibitor-free (CNI), early corticosteroid withdrawal (ESW) regimens with a tacrolimus (TAC)-based ESW…2022 American Transplant Congress
Validation of the iBox Surrogate End Point in CNI Free, Belatacept Treated Patients (BENEFIT & BENEFIT-EXT)
*Purpose: The iBox is a prognostication system for long-term kidney allograft survival, developed with mostly patients under a CNI based immunosuppression. Patients treated with a…2022 American Transplant Congress
Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study
Paris Transplant Group, INSERM, Paris, France
*Purpose: Conversion to belatacept after transplant seems to be safe. However, no studies have reported the long-term efficacy and safety outcomes after conversion to belatacept…2022 American Transplant Congress
CD8+ T Cells Differentiate into a CD43-expressing Effector Population After Transplantation
Department of Pathology, Johns Hopkins University, Baltimore, MD
*Purpose: Despite a significantly reduced toxicity profile and improved long-term graft function versus calcineurin inhibitors, widespread adaptation of belatacept (CTLA-4 Ig) has been limited due…2022 American Transplant Congress
Conversion to Belatacept for Calcineurin Inhibitor Toxicities
Columbia University Medical Center, New York, NY
*Purpose: Calcineurin inhibitors (CNIs) have improved renal transplant (RTx) outcomes but are associated with significant toxicities. Belatacept provides better long-term outcomes than cyclosporine, has less…2021 American Transplant Congress
AT-1501, a Novel and Clinically Applicable CD40L Specific Monoclonal Antibody, Promotes Islet Allograft Survival in Nonhuman Primates
*Purpose: Immune intervention with a CD40L specific monoclonal antibody (mAb, Hu5c8, Biogen) has previously been shown to safely and effectively prevent islet allograft (IA) rejection…2021 American Transplant Congress
Interruption of Notch Signaling via Blockade of Delta-Like Ligand 4 Prevents Co-Stimulation Blockade Resistant Allograft Rejection
Emory University Department of Surgery, Atlanta, GA
*Purpose: Co-stimulation blockade (CoB) has emerged as a promising immunosuppression strategy with the advent of Belatacept, a novel CTLA4-Ig fusion protein that blocks CD28-mediated T…2021 American Transplant Congress
The Microenvironment of Belatacept-Resistant Rejection
Surgery, Emory University, Atlanta, GA
*Purpose: Belatacept is a co-stimulation blockade immunosuppressant, that despite demonstrating improved long-term outcomes, has not been widely adopted, in part, due to concern over early…2021 American Transplant Congress
IFNγ, and to a Lesser Extent TNFα, Elicits Protracted Endothelial Cell Expression of Costimulatory Molecules and Antigen Presentation Machinery
Pathology and Laboratory Medicine, UCLA, Los Angeles, CA
*Purpose: Beyond simply “recruiting” leukocytes to sites of injury, local stimulation by the donor vascular compartment may prolong alloimmune responses. Moreover, the dynamics of endothelial…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 30
- Next Page »